Search results
BMS.com. Discover what it means to have a meaningful career. At Bristol Myers Squibb, you'll transform patients' lives and help them prevail over serious diseases.
Bristol Myers Squibb focuses on developing new medicines to address the unmet medical needs of patients with serious diseases. Explore comprehensive information about our products including dosage and safety information.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology ...
Jun 24, 2022 · Bristol Myers Squibb: Creating a Better Future for People with Cancer. Bristol Myers Squibb is inspired by a single vision—transforming patients’ lives through science. The goal of the company’s cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Feb 4, 2022 · Bristol Myers Squibb posted fourth quarter revenues of $12.0 billion, an increase of 8%, driven by Eliquis, our Immuno-Oncology and new product portfolios. U.S. revenues increased 11% to $7.5 billion in the quarter. International revenues increased 4% to $4.5 billion in the quarter.
Get the latest Bristol-Myers Squibb Co (BMY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Oct 8, 2023 · Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRAS G12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a ...
